Accurate differentiation between Crohn's disease and ulcerative colitis is important to ensure early and appropriate therapeutic intervention.
Dr Amanda Starr and colleagues identified proteins that enable differentiation between Crohn's disease and ulcerative colitis in children with new onset IBD.
Mucosal biopsies were obtained from children undergoing baseline diagnostic endoscopy prior to therapeutic interventions.
Using a super-stable isotope labeling with amino acids in cell culture (SILAC)-based approach, the proteomes of 99 pediatric control and biopsies of patients with Crohn's disease and ulcerative colitis were compared.
Multivariate analysis of a subset of these was applied to identify novel biomarkers, which were validated in a second subset.
|90% treatment retention was observed at 6 months after start of TNFi |
In the discovery cohort, the team found that a panel of 5 proteins was sufficient to distinguish control from IBD-affected tissue biopsies with an area under the curve of 1.0.
The researchers observed that a second panel of 12 proteins segregated inflamed Crohn's disease from ulcerative colitis within an area under the curve of 0.95.
Application of the 2 panels to the validation cohort resulted in accurate classification of 96%, and 80% of patients.
The team identified 116 proteins to have correlation with the severity of disease, 4 of which were components of the 2 panels, including visfatin and metallothionein-2.
Dr Starr's team concludes, "This study has identified 2 panels of candidate biomarkers for the diagnosis of IBD, and the differentiation of IBD subtypes to guide appropriate therapeutic interventions in paediatric patients."